Clinical Trial Update: Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

View source ↗

Summary

A completed clinical trial reports outcomes for patients with resectable non-small cell lung cancer who received neoadjuvant nivolumab in combination with chemo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-small Cell Lung Cancer (NSCLC) | Status: COMPLETED